Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),...

Related Keywords

Canada ,China ,Italy ,Boston ,Massachusetts ,United States ,Sweden ,United Kingdom ,France ,Canadian ,Chiesi Farmaceutici ,Giacomo Chiesi ,Fernando Tricta ,B Corp ,Berry Company Public Relations ,Group Chiesi ,Chiesi Group ,Health Canada ,Group Research ,Us Food Drug Administration Approved Indication ,Global Rare Diseases ,Chiesi Global Rare ,Drug Administration Approved Indication ,Important Safety ,Diamond Blackfan ,Benefit Corporation ,Global Rare ,Chiesi Global Rare Diseases ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,International Medical Approval ,